Glutathione S-transferase mu 2
AltitudeomicsDB
Protein Official symbol |
GSTM2 |
Aliases |
GSTM2 GST4 |
Chromosomal Location |
1 |
Length |
218 |
Uniprot ID |
P28161 |
EC number |
2.5.1.18 |
Protein family Information(Pfam) |
PF00043;PF02798; |
PDB id |
1HNA;1HNB;1HNC;1XW5;1YKC;2AB6;2C4J;2GTU;3GTU;3GUR;5HWL; |
InterPro ID |
IPR010987;IPR036282;IPR040079;IPR004045;IPR004046;IPR003081;IPR036249; |
dbSNP |
rs2229050 |
AltitudeomicsDB
Protein 1 |
Protein 2 |
Combine Score |
GSTM3 |
GSTM2 |
0.99 |
GSTM4 |
GSTM2 |
0.985 |
GSTM1 |
GSTM2 |
0.96 |
GSTM4 |
GSTM5 |
0.959 |
GSTM5 |
GSTM2 |
0.959 |
GSTM4 |
GSTM3 |
0.952 |
GSTM3 |
GSTM5 |
0.939 |
GSTM1 |
GGH |
0.905 |
GSTM4 |
GGH |
0.905 |
GGH |
GSTM5 |
0.902 |
GGH |
GSTM2 |
0.902 |
GGH |
GSTM3 |
0.902 |
Gene Ontology Semantic Similarity
Download Tab separated file
# |
2946 (GSTM2) |
2949 (GSTM5) |
2947 (GSTM3) |
8836 (GGH) |
2948 (GSTM4) |
2944 (GSTM1) |
2946 (GSTM2)
|
1.00
|
0.77
|
0.91
|
0.17
|
0.92
|
0.88
|
2949 (GSTM5)
|
0.77
|
1.00
|
0.87
|
0.19
|
0.83
|
0.77
|
2947 (GSTM3)
|
0.91
|
0.87
|
1.00
|
0.16
|
0.98
|
0.96
|
8836 (GGH)
|
0.17
|
0.19
|
0.16
|
1.00
|
0.17
|
0.17
|
2948 (GSTM4)
|
0.92
|
0.83
|
0.98
|
0.17
|
1.00
|
0.98
|
2944 (GSTM1)
|
0.88
|
0.77
|
0.96
|
0.17
|
0.98
|
1.00
|
Association with High Altitude
Protein Official symbol |
Source Organism |
Tissue of Expression |
Level of hypoxia |
Altitude |
Duration of experiment |
Level of expression |
Fold change |
Experiment details |
geographical location |
ethnicity of the patients |
Control group |
Control (Fold change) |
Reference (PMID) |
GSTM2 |
Human |
Skeletal muscle |
- |
4559 m |
9 day |
downregulated |
-1.51 |
2-DIGE |
Southern Europe |
Italians |
1 |
Fasting control subjects at laboratory in Copenhagen with no caffeine intake |
18937252 |
Association with TF
TF |
TF Entrez |
Gene |
Gene Entrez |
Type |
PMID |
Database |
Association with miRNA
miRTarBase ID |
miRNA |
Species (miRNA) |
Protein Official Symbol |
Human Entrez ID |
Species (Target Gene) |
Experiments |
Support Type |
References (PMID) |
MIRT025057 |
hsa-miR-181a-5p |
Homo sapiens |
GSTM2 |
2946 |
Homo sapiens |
Microarray |
Functional MTI (Weak) |
17612493 |
Gene Ontology
ID |
GO ID |
GO Term |
GO Type |
2946 |
GO:0018916 |
nitrobenzene metabolic process |
GOTERM_BP_DIRECT |
2946 |
GO:0042803 |
protein homodimerization activity |
GOTERM_MF_DIRECT |
2946 |
GO:0016529 |
sarcoplasmic reticulum |
GOTERM_CC_DIRECT |
2946 |
GO:0098869 |
cellular oxidant detoxification |
GOTERM_BP_DIRECT |
2946 |
GO:0070458 |
cellular detoxification of nitrogen compound |
GOTERM_BP_DIRECT |
2946 |
GO:1901687 |
glutathione derivative biosynthetic process |
GOTERM_BP_DIRECT |
2946 |
GO:0004364 |
glutathione transferase activity |
GOTERM_MF_DIRECT |
2946 |
GO:0005737 |
cytoplasm |
GOTERM_CC_DIRECT |
2946 |
GO:0043651 |
linoleic acid metabolic process |
GOTERM_BP_DIRECT |
2946 |
GO:0010880 |
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum |
GOTERM_BP_DIRECT |
2946 |
GO:0010881 |
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion |
GOTERM_BP_DIRECT |
2946 |
GO:0055119 |
relaxation of cardiac muscle |
GOTERM_BP_DIRECT |
2946 |
GO:0005102 |
receptor binding |
GOTERM_MF_DIRECT |
2946 |
GO:0043295 |
laminin binding |
GOTERM_MF_DIRECT |
2946 |
GO:0060316 |
positive regulation of ryanodine-sensitive calcium-release channel activity |
GOTERM_BP_DIRECT |
2946 |
GO:0006749 |
glutathione metabolic process |
GOTERM_BP_DIRECT |
2946 |
GO:0008152 |
metabolic process |
GOTERM_BP_DIRECT |
2946 |
GO:0004602 |
peroxidase activity |
GOTERM_MF_DIRECT |
2946 |
GO:0005515 |
protein binding |
GOTERM_MF_DIRECT |
2946 |
GO:0070062 |
extracellular exosome |
GOTERM_CC_DIRECT |
2946 |
GO:0019899 |
enzyme binding |
GOTERM_MF_DIRECT |
2946 |
GO:0005829 |
cytosol |
GOTERM_CC_DIRECT |
2946 |
GO:0042178 |
xenobiotic catabolic process |
GOTERM_BP_DIRECT |
2946 |
GO:0060315 |
negative regulation of ryanodine-sensitive calcium-release channel activity |
GOTERM_BP_DIRECT |
2946 |
GO:0014809 |
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion |
GOTERM_BP_DIRECT |
2946 |
GO:0071313 |
cellular response to caffeine |
GOTERM_BP_DIRECT |
Pathways
Human Entrez ID |
KEGG ID |
KEGG Term |
2946 |
hsa00480 |
Glutathione metabolism |
2946 |
hsa00980 |
Metabolism of xenobiotics by cytochrome P450 |
2946 |
hsa00982 |
Drug metabolism - cytochrome P450 |
2946 |
hsa05204 |
Chemical carcinogenesis |
Association with Disease
Protein Official Symbol |
Human Entrez ID |
Disease Name |
Disease Id |
Disease Semantic Type |
Semantic score |
DSI |
DPI |
Disease Type |
GSTM2 |
2946 |
Kidney Failure, Acute |
C0022660 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Acute kidney injury |
C2609414 |
Injury or Poisoning |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Myocardial Ischemia |
C0151744 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Degenerative Diseases, Spinal Cord |
C0751733 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Down Syndrome |
C0013080 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Degenerative Diseases, Central Nervous System |
C0270715 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
group |
GSTM2 |
2946 |
Drug-Induced Liver Disease |
C0860207 |
Disease or Syndrome |
0.32 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Non-Small Cell Lung Carcinoma |
C0007131 |
Neoplastic Process |
0.31 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Hepatitis, Toxic |
C0019193 |
Injury or Poisoning |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Drug-Induced Acute Liver Injury |
C3658290 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Acute Kidney Insufficiency |
C1565662 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Neurodegenerative Disorders |
C0524851 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
group |
GSTM2 |
2946 |
Trisomy 21, Mitotic Nondisjunction |
C0751081 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Down Syndrome, Partial Trisomy 21 |
C0432416 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Hepatitis, Drug-Induced |
C1262760 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Chemically-Induced Liver Toxicity |
C4279912 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Chemical and Drug Induced Liver Injury |
C4277682 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Trisomy 21, Meiotic Nondisjunction |
C0432417 |
Disease or Syndrome |
0.3 |
0.517 |
0.793 |
disease |
GSTM2 |
2946 |
Schizophrenia |
C0036341 |
Mental or Behavioral Dysfunction |
0.33 |
0.517 |
0.793 |
disease |
Association with Drug
Protein Official Symbol |
Human Entrez ID |
drug_claim_primary_name |
drug_name |
drug_chembl_id |
interaction_types |